

Supplemental Figure S1

TITLE: Lycorine suppresses RANKL-induced osteoclastogenesis in vitro and prevents ovariectomy-induced osteoporosis and titanium particle-induced osteolysis in vivo

AUTHORS: Shuai Chen, Gu Jin, Kang-Mao Huang, Jian-Jun Ma, Qiang Wang, Yan Ma, Xiao-Zhen Shen, Zhi-Jie Zhou, Zhi-Jun Hu, Ji-Ying Wang, An Qin, Shun-Wu Fan










A**B****C****D****E****F****G****H****I**

Fig. S1. LY effectively prevents OVX-induced bone loss *in vivo*. (A): The body weight of mice 0-6 weeks after OVX in Sham, Vehicle, Low dose and High dose groups (** $P < 0.01$). (B): The weight of the mouse uteri at the time of sacrifice in all four groups (** $P < 0.01$). (C): The left tibiae of all mice were scanned with a high-resolution micro-CT. (D)-(H): The calculation of the microstructural indices was performed for the micro-CT data as described in the Methods section. Microstructural indices include bone volume/tissue volume (BV/TV), bone surface/bone volume (BS/BV), trabecular separation (Tb.Sp.), trabecular thickness (Tb.Th.), and trabecular number (Tb.N.) ($*P < 0.05$; ** $P < 0.01$). (I): the tibiae were fixed in 4% paraformaldehyde, then decalcified, embedded and sectioned as described in the Methods section. Sections of tibiae were stained with H&E (40 \times and 100 \times) and TRAP (100 \times and 200 \times).